The tumor-promoting arm of transforming growth factor beta (TGF-) receptor signaling contributes to advanced cancer progression and is considered a master regulator of breast cancer metastasis. In mammals, there are six distinct members in the tumor-necrosis factor receptor (TNFR)-associated factor (TRAF) family (TRAF1-TRAF6), with the function of TRAF4 not being extensively studied in the past decade. Although numerous studies have suggested that there is elevated TRAF4 expression in human cancer, it is still unknown in which oncogenic pathway TRAF4 is mainly implicated. This review highlights TGF--induced SMAD-dependent signaling and non-SMAD signaling as the major pathways regulated by TRAF4 involved in breast cancer metastasis.
Transforming growth factor beta (TGF-) receptor signaling drives cancer metastasis, and the stability and membrane localization of its receptor is an important determinant in controlling the intensity and duration of TGF-β signaling. A genome-wide cDNA screen identified multiple important positive regulators of TGF-β-SMAD signaling [1] [2] [3] . Among them, a distant tumor-necrosis factor receptor (TNFR)-associated factor (TRAF) family member, TRAF4, is of interest as it could target different substrates to play positive roles in both SMAD-dependent and SMADindependent TGF-β signaling. This apparently contributes to tumor cell migration. Importantly, TRAF4 gene copy number is increased in multiple cancer types and amplified the most in breast cancer patients. Variations in TRAF4 expression accordingly modulate signaling readout and also TGF-β promoted phenotypes such as epithelial to mesenchymal transition (EMT) and tumor cell invasion and metastasis.
In vivo experiments involving established animal metastasis models have verified the critical role that TRAF4 plays, and analyses of human patient samples further confirmed that TRAF4 correlates with poor prognosis. In this short review, we introduce both the background and work in progress on TRAF4-regulated TGF-β receptor signaling. We propose a working model of TRAF4 and highlight its critical role in controlling breast cancer metastasis.
TRAF4, an unusual TRAF family member
The TRAF family consists of six members. Except for TRAF4, all other TRAFs were identified in a yeast two-hybrid screen using cytoplasmic domains from various members of the TNFR family [4] . Since the original study that identified TRAF1 and TRAF2 as the first members associating with TNFR2, the following work has provided strong evidence that TRAF2, TRAF3, TRAF5 and TRAF6 are all involved in either canonical or alternative nuclear factor-κB (NF-κB) activation. (For the distinct role of these TRAFs in NF-κB signaling pathways, we refer the reader to an excellent review [4] .)
While later studies verified that TRAF1, TRAF2, TRAF3, TRAF5 and TRAF6 acted as adaptor proteins for various cell surface TNFRs and interleukin-1/Toll-like receptors (IL-1R/TLR) to mediate activation of NF-κB and activator protein 1 (AP1), it has not yet been demonstrated that TRAF4 functions in a similar manner [4, 5] . Although all TRAF proteins share largely the same structure, such as an N-terminal RING finger domain, a middle zinc finger domain (not in TRAF1) and a conserved C-terminal TRAF domain, simplified in a comparison between TRAF4 and TRAF6 (Figure 1 ), TRAF4 seems to be unique as it is the only member that has seven zinc finger repeats (TRAF2, TRAF3, TRAF5 and TRAF6 contain five zinc finger repeats) [4] . Functionally distinct from other TRAFs that are mainly involved in the immune system [6, 7] , TRAF4 does not seem to play a role in the immune system as no immunological defects have been identified in mice lacking TRAF4 [8, 9] .
TRAF4, an amplified gene in breast cancer
As a RING domain-containing E3 ligase, TRAF4 was originally identified in a differential expression screen using a cDNA library of breast cancer-derived metastatic lymph nodes [10] . Further study showed that TRAF4 overexpression was a common characteristic of human carcinomas [11] . This is likely due to amplification or gain of gene copies in cancer. The TRAF4 gene, which is located in an amplified region of chromosome, is amplified in breast cancer and this is correlated with ERBB2 amplification in breast cancer patients [3, 12] . Importantly, analysis of data from the TCGA database showed that TRAF4 gene amplification was also found in many other types of cancer, such as bladder urothelial carcinoma and ovarian cancer, suggesting that TRAF4 is oncogenic and its possible role is not limited to breast cancer [3] . The pro-oncogenic role of TRAF4 is linked to the altering of cell mobility since the TRAF4-deficient mice showed impaired neural tube closure and tracheal ring disruption, both of which are closely associated with abnormal cell migration [8, 9] .
TGF-, a master regulator of breast cancer metastasis
Cancer is a complex disease with multiple cellular signaling pathways that are cross-regulated. TGF-β signaling is tumor suppressive in the pre-malignant stage but contributes to malignant cancer progression by serving as a strong driving force for cancer metastasis [13, 14] . Type II and type I serine/threonine kinase receptors (TβRII and TβRI, respectively) mediate TGF-β signals. Upon binding of the TGF-β ligand, TβRII and TβRI form a heteromeric receptor complex. Phosphorylation of TβRI by TβRII on serine and threonine residues in a glycine/serine-rich domain triggers TβRI kinase activity. The activated TβRI phosphorylates downstream SMAD2/SMAD3 to induce its association with SMAD4, which accumulates in the nucleus and regulates transcription [13] [14] [15] [16] . SMAD complex-mediated transcriptional induction of mesenchymal markers and pro-migratory genes provide the TGF- pathway with a potent role in driving EMT and promoting invasion and metastases in advanced cancers [17, 18] .
Recent discoveries have shown that activation of SMAD-independent pathways by TGF-β also contribute to the pro-oncogenic role of TGF-β in malignant tumors [17, 19, 20] . In line with this, positive effects from anti-TGF-β signaling therapies have been shown to reduce breast cancer invasion and metastasis [21] [22] [23] [24] [25] [26] . Efficient TGF-β pathway inhibitory drugs have been developed and tested in preclinical studies, and some are currently in clinical trials showing expected results [27, 28] .
TRAFtargets SMURF2 degradation and mediates SMAD activation by TGF-
The pulse and duration of TGF-β signaling is mainly controlled by TGF-β receptor activity. While the inhibitory SMAD7-SMURF2 complex targets TGF-β receptor for polyubiquitination and inhibits downstream SMAD activation, deubiquitinases, USP4/15, remove ubiquitin chains from TβRI, thus stabilizing the TGF-β receptor [2, 29, 30] . In a proteomic tandem affinity purification (TAP) screen, SMURF2 was identified as a strong binding partner of TRAF4 [3] . As a substrate, SMURF2 triggered polyubiqui-tination and degradation by TRAF4 [3] . Inversely, as a HECT domain-containing E3 ligase, SMURF2 could also initiate polyubiquitin conjugation on TRAF4, resulting in TRAF4 protein degradation via the proteasome [3] ( Figure  2A ). These observations raise an interesting question as to when and where these two E3 ligases interact with each other.
In response to TGF-β and in a time-dependent but SMAD7-independent manner, TRAF4 was observed to be recruited to the TGF-β receptor complex prior to the recruitment of SMURF2 [3] . This indicates that a sequential binding event occurred on the TGF-β receptor; in other words, during TGF-β signaling, the receptor dictates transient activation (recruitment) of TRAF4 and degradation of SMURF2, eliminating the negative impact of SMURF2 on signaling, at least in the period when signaling is just initiated [31] . Evidence shows that the receptor-TRAF4 association precedes SMURF2 recruitment, and receptor-bound TRAF4 actively ubiquitylates and degrades SMURF2 [3, 31] . Biotin could be used to label the TGF-β receptor largely on the cell membrane, thus streptavidin beads could allow for the pull-down of the active membrane-located TGF-β receptor. It has been noted that TRAF4 action on (eliminating) SMURF2 could positively impact active TβRI levels [3] . Consistently, TRAF4-deficient mouse embryonic fibroblasts appear less responsive to TGF-β as a readout of SMAD activation [3] . Therefore, elimination of SMURF2 by TRAF4 apparently contributes to TGF-β receptor stability on the plasma membrane. 
TRAF4 stimulates TAK1-mediated activation of non-SMAD TGF- signaling
In response to TGF-β stimulation, TβRI-associated TRAF4 protein rapidly undergoes degradation-independent ubiquitination in which the K63-linked polyubiquitin chain is clearly identified [3] . This in turn stimulates TAK1 (and p-TAK1), a ubiquitin-dependent kinase that is also activated by other TRAF family members [32] [33] [34] [35] . Similar to the actions of other TRAF members and distinctly in response to the TGF-β receptor but not TNFR, K63-polyubiquitination of TRAF4 recruits/activates TAB-TAK1 [3], a protein kinase that stimulates activity of MKK and IKK. These latter two kinases can activate the p38 kinase/JNK kinase and NFB pathways for multiple downstream readouts [32] ( Figure 2B) ; consistently, gathered evidence from TRAF4 depleted cells suggests an impaired p38/NFB activation by TGF-β [3]. Therefore, TRAF4 mediates TAK1-dependent non-SMAD TGF-β signaling ( Figure 2B ).
TRAF4 contributes to breast cancer metastasis
Influenced by stromal cells, primary tumor cells undergo EMT or use other means to invade the circulation and become circulating tumor cells (CTCs) [36] . CTCs are protected by platelets and further undergo EMT due to TGF-β signaling. Tumor-derived factors and exosomes mobilize bone marrow-derived cells to form a pre-metastatic niche to promote the seeding and expansion of metastasis and stromal components at the metastasis niches that enhance tumor survival, stemness and immune evasion [37] . In epithelial-like breast cancer cells, TRAF4 depletion impaired EMT, and in mesenchymal-like cells, TRAF4 depletion led to loss of cell mobility. Consistently, TRAF4-deficient cells exhibited enhanced cell-cell adherence and reduced cell migratory capacity; importantly, in vivo analysis showed a loss of metastasis upon TRAF4 depletion in zebrafish and mice xenograft models that were dependent on TGF-β receptor signaling [3] . Additionally, SMURF1-mediated lysine 190 ubiquitination of TRAF4 is thought to target TRAF4 to tight-junctions, where TRAF4 was recently proven to interact with phosphoinositides (PIPs) to increase cell mobility [38, 39] .
TRAF4 correlates with poor prognosis in breast cancer patients
In line with the TRAF4 gene amplification and the function of TRAF4 in driving breast cancer metastasis, TRAF4 levels correlated with both SMAD and TAK1 activation and poor prognosis, as observed in over 500 breast cancer pa- [40, 41] . The P-value was calculated using a log-rank test.
tients [3] . Analyses have suggested that high TRAF4 expression is an indicator of poor outcome in cancer patients [3] . Furthermore, in a broader analysis where TRAF4 level was examined in further detail, in which patients were stratified into low (33%), middle (33%) and high (33%) expression groups, a clear trend associating TRAF4 level with outcome was clearly observed (Figure 3 ). There was apparently poor disease-free survival for the middle TRAF4 level and an even worse outcome for patients with a high TRAF4 level ( Figure 3A) . When distant metastasis-free survival was taken into account, a similar statistically significant trend was also apparent when patients were divided into the same TRAF4 expression groups as above ( Figure 3B and 3C). Taken together with all the biochemical findings and clinical analyses, the results demonstrate that TRAF4 could be regarded as a biomarker for a subset of breast cancer patients, for which anti-TGF-β therapy might be effective.
Conclusion
As a more distant member of the TRAF family, TRAF4 has not been linked to TNF receptor or Toll-like receptor function. It was recently found to promote signaling of the TGF-β family by associating with the TGF-β receptor and antagonizing SMURF2 function as an amplified gene in breast cancer. As E3 ligase activity is druggable, both in vitro and in vivo evidence has exposed TFAF4 as a putative biomarker for malignant breast cancer progression and a possible therapeutic target. 
